Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV20001

Result Summary for APV20001

Result Summary

Protocol ID:	APV20001
Clinical Study ID:	APV20001 Open Label Phase
Official Title:	Open-Label Phase Report of: A Randomized, Multicenter, Partially Double-Blinded, Repeat Dose, Cross-Over Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Effect of Two Doses of FPV Compared with AGENERASE(1200mg BID) when Given for 28 Days to Subjects Infected with HIV-1
Phase:	Phase 2
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	lexiva;lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Abstract: Effects of formulation and dosing strategy on amprenavir (apv) concentrations (c) in the seminal plasma (sp). Chaudry, N , Eron, J. , Naderer, O. , Pereira, A. , Fiscus, S. , Wire, M. B. , and Kashuba, A. 4th International Workshop on Clinical Pharmacology of HIV Therapy 3/27/2003 Cannes; France Abstract: GW433908, a novel prodrug of the hiv protease inhibitor (p1) amprenavir (apv): safety, efficacy, and pharmacokinetics (pk) (apv20001). R. Wood*I, K. Arasteh2 R. Pollard3 P. Kaur4 0. Nadarer4 and M. B. Wire4. 8th Conference on Retroviruses and Opportunistic Infections 2/4/2001 Chicago, IL; USA Wood R, Arasteh K, Stellbrink HJ, et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of FPV and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004;48(1):116-23.